Medpace Holdings, Inc.
- MEDP
- NASDAQ
- Medical - Diagnostics & Research
- Clinical Research (CRO)
- Drug Development Outsourcing
$618.23
Today −0.04%Quote Oct 19, 2026, 01:54 PM UTC
+0.53%over the last month
Max drawdown −5.1%From 1-month high −1.9%3 months +17.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$17.26B
Quote Oct 19
Next earnings
Oct 21
Expected, not confirmed
Analyst target
$620.44
+0.4% from here
Floor
$615.05
0.5% below price
Where the price sits
19 analysts
Analyst range, low to high
$515.00$700.00
- Price $618.23
- Resistance $624.13–$630.40
- Consensus $620.44
The price is just above its floor and right under resistance. Analysts' average target sits about 0% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about MEDPPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $707.3M
- Metabolic$219.1M31.0%
- Oncology$209.4M29.6%
- Other$98.3M13.9%
- Central Nervous System$82.9M11.7%
- Cardiology$60.0M8.5%
- Antiviral And Anti Infective$37.8M5.3%
Industry
Medical - Diagnostics & Research
Employees
6,500